Navigation Links
Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018

WALTHAM, Mass., Nov. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the next decade, modest growth in the methicillin-resistant Staphylococcus aureus (MRSA) drug market will be driven in part by the uptake of three emerging agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/AstraZeneca/Takeda. The increasing prevalence of MRSA and the uptake of several premium-priced emerging therapies will drive the MRSA market to increase from $740 million in 2008 to more than $1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Methicillin-Resistant Staphylococcus Aureus finds that Theravance/Astellas's telavancin, Johnson & Johnson/Basilea's ceftobiprole and Forest/AstraZeneca/Takeda's ceftaroline will capture more than one-third of the overall MRSA market in 2018. The two novel first-in-class anti-MRSA cephalosporins -- ceftobiprole and ceftaroline -- which are both expected to launch by 2011, will have a significant impact on the market by bringing cephalosporins to the forefront of the array of drug classes used to treat MRSA. Owing to their broad-spectrum and expanded activity against MRSA, ceftobiprole and ceftaroline are well-poised for use as first-line therapies for suspected MRSA infections in the hospital setting.

"Ceftobiprole and ceftaroline offer safe, effective, and convenient monotherapy options for simplified empiric treatment of MRSA infections in place of existing combination therapy," said Decision Resources Analyst Hemali Patel, Ph.D. "Although we anticipate robust competition between these two agents due to their similar profiles, we forecast that ceftobiprole and ceftaroline will each achieve significant commercial success and together will represent 20 percent of the overall MRSA market in 2018."

The report also finds that, in contrast to current therapies consisting largely of narrow-spectrum anti-MRSA agents, late-stage anti-MRSA emerging therapies are comprised of numerous broad-spectrum agents spanning several antibiotic drug classes. In addition, the pipeline for MRSA is also characterized by new therapies being developed in both intravenous and oral formulations (e.g., Trius Therapeutics' torezolid, Rib-X's delafloxacin, Paratek/Novartis's PTK-0796) which could address the growing need for oral MRSA therapies for both the hospital and community settings.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                  Decision Resources, Inc.
    Christopher Comfort                 Elizabeth Marshall
    781-296-2597                        781-296-2563   

SOURCE Decision Resources

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Corp. to Present at the Sidoti Emerging Growth Research Institutional Investor Forum
2. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
3. Cancer Drugs Emerging as Top Driver of Specialty Drug Spending
4. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
5. Patient-Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
8. Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children
9. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
10. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
11. Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
Post Your Comments:
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid ... America. As people age, more care is needed, especially with Alzheimer’s, dementia and ... professionals are being overworked. The forgotten part of this equation: 80 percent of ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any ... opener. Utilize presets featuring self-animating drop zones, lines, bars, and text with the ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... Karnataka (PRWEB) , ... November 27, 2015 , ... ... world, Health-E-minds, an innovative online platform for mental health and wellness consultation, has ... , This partnership will bridge the knowledge gap experienced by parents and bring ...
Breaking Medicine News(10 mins):